Nanotechnology-Driven Bioavailability Enhancement: A Critical Review of BCS Class II and IV Drugs. JDDHS [Internet]. 2026 Sep. 16 [cited 2026 Sep. 17];3(03):63-71. Available from: https://jddhs.com/index.php/jddhs/article/view/146